8-K: Alumis Completes Merger with ACELYRIN, Creating Leading Clinical Stage Biopharma Company

Alumis Inc. has finalized its merger with ACELYRIN, Inc., establishing a prominent clinical-stage biopharmaceutical company with a diverse portfolio and robust financial position.

Summary

• Alumis Inc. has completed its merger with ACELYRIN, Inc. on May 21, 2025.
• Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned.
• ACELYRIN common stock will no longer be listed on the NASDAQ Global Select Market.
• The merger strengthens Alumis' balance sheet, extending its cash runway into 2027.
• Lynn Tetrault has been appointed to the Alumis Board of Directors.
• Henry Gosebruch will no longer be joining the Board due to his appointment as CEO of Galapagos.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of the merger, the strengthened financial position, and the appointment of a new board member. The forward-looking statements are cautiously optimistic.

Positives

• The merger strengthens Alumis' balance sheet, extending its cash runway into 2027.
• Alumis now has a differentiated late-stage portfolio to develop transformative therapies.
• Lynn Tetrault has been appointed to the Alumis Board of Directors, bringing additional expertise.
• The combined company is positioned as a leading clinical-stage biopharma company.

Negatives

• Henry Gosebruch will no longer be joining the Alumis Board of Directors.

Risks

• The company faces risks related to advancing ESK-001 and obtaining regulatory approval for its clinical candidates.
• There are risks associated with the timing and results of preclinical and clinical trials.
• Alumis faces risks related to funding development activities and achieving development goals.
• The company faces risks related to protecting its intellectual property.

Future Outlook

Alumis aims to advance its pipeline through multiple planned key data readouts and develop transformative therapies for patients, while remaining disciplined in its operations and capital plan.

Management Comments

• Martin Babler, President, CEO and Chairman of Alumis, stated that the merger allows the company to advance its pipeline and deliver significant benefits for patients and stockholders.

Industry Context

The merger positions Alumis as a more competitive player in the biopharmaceutical industry, particularly in the development of therapies for immune-mediated diseases. The company's strengthened financial position and diversified pipeline could attract further investment and partnerships.

Comparison to Industry Standards

• Alumis' focus on immune-mediated diseases aligns with a growing trend in the biopharmaceutical industry, with companies like Bristol Myers Squibb and AbbVie also heavily invested in this area.
• The company's cash runway extending into 2027 provides a competitive advantage compared to smaller biotechs that often face funding challenges.
• The merger with ACELYRIN is similar to other strategic acquisitions in the industry, such as Pfizer's acquisition of Arena Pharmaceuticals, aimed at expanding pipelines and market presence.

Management Changes

Related Party Transactions

• Ms. Tetrault received consideration in respect of her equity interests in ACELYRIN in connection with the Merger.

Stakeholder Impact

• Shareholders of ACELYRIN received Alumis common stock.
• Alumis stockholders may benefit from the strengthened financial position and diversified pipeline.
• Patients may benefit from the development of new therapies for immune-mediated diseases.

Next Steps

• Alumis will file the financial statements and pro forma financial information related to the acquisition within 71 days.
• Alumis plans to enter into its standard form of indemnification agreement for directors and executive officers with Ms. Tetrault.
• Alumis will advance its pipeline through multiple planned key data readouts.

Key Dates

Keywords

merger, ACELYRIN, Alumis, biopharma, clinical stage, portfolio, therapies, immune-mediated diseases, ESK-001, lonigutamab